At the time of writing, Cellectar Biosciences Inc [CLRB] stock is trading at $2.95, up 7.66%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CLRB shares have gain 9.67% over the last week, with a monthly amount drifted -20.91%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ROTH Capital started tracking the stock assigning a Buy rating. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $2.70 as its price target on December 21, 2016.
For the past year, the stock price of Cellectar Biosciences Inc fluctuated between $2.45 and $20.59. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Cellectar Biosciences Inc [NASDAQ: CLRB] shares were valued at $2.95 at the most recent close of the market. An investor can expect a potential return of 306.78% based on the average CLRB price forecast.
Analyzing the CLRB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.29, Equity is -1.91 and Total Capital is -3.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.77 points at the first support level, and at 2.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.07, and for the 2nd resistance point, it is at 3.19.
Ratios To Look Out For
It is important to note that Cellectar Biosciences Inc [NASDAQ:CLRB] has a current ratio of 2.77. As well, the Quick Ratio is 2.77, while the Cash Ratio is 2.56.
Transactions by insiders
Recent insider trading involved NEIS JOHN, Director, that happened on Dec 12 ’25 when 198.0 shares were sold. Chief Executive Officer, CARUSO JAMES V completed a deal on Jul 02 ’25 to buy 10000.0 shares. Meanwhile, Chief Operating Officer Longcor Jarrod bought 10000.0 shares on Jul 02 ’25.
